Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has received an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $52.3333.

A number of research firms have recently weighed in on KNSA. TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 target price for the company. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Wedbush increased their price objective on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, The Goldman Sachs Group boosted their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 12,000 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $41.89, for a total transaction of $502,680.00. Following the transaction, the chief financial officer owned 19,086 shares of the company’s stock, valued at approximately $799,512.54. This trade represents a 38.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Barry D. Quart sold 20,129 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $41.51, for a total value of $835,554.79. Following the sale, the director owned 12,546 shares of the company’s stock, valued at $520,784.46. This represents a 61.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 510,689 shares of company stock worth $20,009,290 in the last ninety days. 53.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP boosted its stake in Kiniksa Pharmaceuticals International by 2.3% during the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after purchasing an additional 90,194 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 22.6% in the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after buying an additional 233,668 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after buying an additional 332,846 shares during the period. Qube Research & Technologies Ltd increased its holdings in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the last quarter. Finally, Millennium Management LLC raised its position in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares during the period. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Trading Up 3.9%

KNSA opened at $39.41 on Friday. The company’s 50 day moving average is $41.35 and its 200-day moving average is $36.75. The company has a market cap of $2.99 billion, a P/E ratio of 87.58 and a beta of 0.04. Kiniksa Pharmaceuticals International has a 1-year low of $18.12 and a 1-year high of $44.42.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same period in the prior year, the firm earned ($0.18) earnings per share. The firm’s revenue for the quarter was up 61.2% compared to the same quarter last year. On average, equities analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.